Barrett Esophagus and Esophageal Cancer: Endoscopic Eradication Therapy

0:00Welcome to Board Pearls. This is episode two of three of the Barrett Esophagus and Esophageal Cancer chapter, in the Esophageal Disorders module. This episode is how you eradicate Barrett's endoscopically, and the whole thing turns on one principle: the segment holds two different kinds of tissue that need two different treatments, in a fixed order. The cancer staging and treatment come in episode three.

0:24Here's the principle. Any visible nodule, plaque, or irregular patch is neoplasia of unknown depth, and the flat lining around it is the field that future neoplasia will grow out of. Those get handled differently. Visible disease gets cut out, because cutting it out produces a tissue specimen that tells you how deep the tumor went. Flat metaplasia gets burned off, because ablation clears a wide area of precursor lining without needing to deliver a specimen. And the order is not optional: resect first, ablate second. If you ablate a visible nodule, you've destroyed the very specimen that tells you whether this patient can stay endoscopic or needs surgery. So a case with a Barrett segment, a one-centimeter nodule, and confirmed high-grade dysplasia is not a case for ablation first; the next step is to resect that nodule, and only once the pathology is back does the flat field get ablated.

1:16Endoscopic mucosal resection is the main way to remove these lesions, and there are two methods. In one, you lift the lesion with a fluid injection underneath, suck the raised mucosa into a cap on the scope, and drop a snare around it. In the other, you band the mucosa like you would a varix and then snare the little pseudopolyp that creates. Either way the specimen comes off with enough depth, the lining plus the layer beneath it, for the pathologist to read how deep the invasion went, whether the margins are clear, and whether there's invasion of lymphatics or vessels.

1:51The reason this counts as the staging step and not just treatment is how often it changes the diagnosis compared with the earlier forceps biopsy, and the change runs in both directions. Most often it downgrades: something read as high-grade dysplasia on a forceps biopsy turns out to be less on the fuller specimen, which is exactly why so many patients sent off for esophagectomy on a forceps read end up needing only ablation once they're properly resected. But sometimes it upgrades, revealing deeper invasion the small biopsy missed, and that's the patient you would have badly undertreated by ablating blindly. So resecting first protects you both ways.

2:31Resection in a single piece works well up to a centimeter and a half or two. Bigger lesions can be taken piecemeal, but then you lose the margin read, because you're reassembling the lesion from fragments with broken edges. That's where endoscopic submucosal dissection comes in: using fine knives to dissect the whole lesion out in one piece no matter its size, giving a clean, unbroken specimen with definitive margins. You want that whenever the lesion is large or its shape suggests deeper invasion, particularly the depressed or mixed depressed-and-elevated morphologies, which are the ones that argue for taking it en bloc rather than piecemeal. The cost of the dissection is a longer procedure, a higher perforation risk, and a harder technique to master, which is why standard resection is still considered adequate for most Barrett lesions and dissection is reserved for the larger or more suspicious ones.

3:22Once the visible disease is resected and the pathology confirms an endoscopically curable depth, you ablate the flat field, and radiofrequency ablation is the default. It delivers a controlled, calibrated burn that destroys the columnar lining and the layer just under it without reaching the deep muscle, so the wound heals back as squamous lining under acid suppression. There's a circumferential balloon device for disease that wraps around and a smaller focal device for leftover tongues, islands, and the junction, and clearing a whole segment usually takes a few sessions spaced a couple of months apart, continued until no Barrett's is left to see or biopsy. The randomized evidence is solid: ablating dysplastic Barrett clears the dysplasia and cuts progression to high-grade disease and cancer compared with just watching. And there's a specific trial supporting ablation for low-grade dysplasia, but with a crucial condition built into it: the low-grade had to be confirmed by an expert pathologist, which is the same procedural point from episode one, since community low-grade reads downgrade to nothing in more than half of cases and aren't adequate grounds for ablation.

4:29Cryotherapy is the alternative, freezing the tissue rather than burning it, either as a spray or through a balloon, causing the cells to die from ice crystals and small-vessel clotting. Its main role is as a salvage option after radiofrequency ablation fails, and it's also useful when there's narrowing or a prior stricture, in very long segments that ablate poorly, and in patients who don't tolerate the burn, since it tends to cause less pain and less stricturing. Argon plasma coagulation has a small role for stray islands of metaplasia after ablation, and the old photodynamic therapy is obsolete now because of high stricture rates and prolonged light sensitivity.

5:08The goal of the whole pathway is complete eradication of intestinal metaplasia, meaning no visible Barrett's and no metaplasia on biopsies of the healed squamous lining and the junction. But that is not a cure, and understanding why drives the follow-up: recurrence happens at a steady rate, and it concentrates right at the junction and just above it, where the ablation reaches least well and where ongoing acid keeps favoring columnar regrowth. So the surveillance after eradication is actually more intensive than before treatment, front-loaded into the first year because that's when most recurrence shows up, then spacing out. At each of those exams you biopsy the junction, because that's where recurrence clusters, and the healed squamous lining just above it, and that second one matters because of buried glands, patches of metaplasia that persist hidden underneath the regenerated squamous surface where you can't see them. Buried glands aren't an artifact or a normal finding; they mean the field wasn't fully eradicated and need directed treatment, usually resecting that segment, because you can't monitor a cancer risk that's hidden below the surface. And twice-daily acid suppression is mandatory throughout, because acid stops the squamous lining from healing and increases recurrence.

6:16Eradication doesn't always succeed, and the patients it fails tend to have long segments, ongoing reflux, narrowing, or high-grade disease at the start. The salvage options are cryotherapy, repeat resection of anything residual, and esophagectomy for the occasional patient with multifocal disease that can't be cleanly cleared. The complications to hold are predictable: the most common is stricture, more likely when resection preceded ablation and when more than half the circumference was treated, and it responds to balloon dilation in almost all cases; bleeding is handled endoscopically; and perforation is rare, a bit higher with dissection and large resections. Chest pain in the days after ablation is expected and managed with topical anesthetics, sucralfate, and strong acid suppression.

7:02So the eradication side comes down to this. The segment holds two kinds of tissue that need two treatments in a fixed order. Resect the visible disease first, because that specimen is the staging test that decides endoscopic versus surgical management. Ablate the flat field second, with radiofrequency ablation as the default, cryotherapy as the salvage after it fails. The endpoint is complete eradication of the metaplasia, which isn't a cure, because recurrence concentrates at the junction and in buried glands, which is why the follow-up is heaviest in the first year and samples both the junction and the healed lining, all under twice-daily acid suppression.

7:41Episode three picks up right where this ends, with the patient whose resected lesion turns out to have invaded past the mucosa, or who shows up with a cancer outside any known Barrett's. That's the esophageal cancer story: the split between adenocarcinoma and squamous cell carcinoma, how it's staged, the mucosa-versus-submucosa line that separates the endoscopic patient from the surgical one, and the combined chemoradiation and chemotherapy regimens for locally advanced disease.

8:08For the full chapter, the practice vignettes, and the topic-tagged question bank, head to board pearls dot com. You'll find the rest of the series on Apple Podcasts, Spotify, or wherever you listen to podcasts. That brings us to the end of episode two of three of chapter four, and I'll see you in the next one.